Shenzhen Yujian Biopharmaceutical

Shenzhen Yujian Biopharmaceutical is a clinical-stage biotechnology company based in Shenzhen, China, dedicated to the discovery and development of innovative small molecule therapeutics for metabolic and endocrine disorders. The company's primary focus is on developing orally bioavailable alternatives to injectable peptide therapies, addressing significant unmet needs in the treatment of chronic diseases. Its lead candidate, YJ-001, is a potent non-peptide GLP-1 receptor agonist currently in Phase 1 clinical trials for type 2 diabetes and obesity. Founded in 2021 by Dr. Yu Jian, the company leverages a robust medicinal chemistry platform to target high-value metabolic pathways. Yujian Biopharmaceutical has secured significant venture capital funding to advance its pipeline of next-generation metabolic treatments.